Updated MIMS summary of H. pylori treatment regimens

The popular quick-reference MIMS summary of NICE guidance on the treatment of Helicobacter pylori has been updated to reflect the latest version of the guideline.

Antibiotic doses provided in the MIMS summary are taken from NICE CKS (cks.nice.org.uk)
Antibiotic doses provided in the MIMS summary are taken from NICE CKS (cks.nice.org.uk)

The updated guide is available online and will appear in the March print issue of MIMS.

Testing for H. pylori

Before starting eradication treatment, the presence of H.pylori should be confirmed using a carbon-13 urea breath test, stool antigen test or locally validated laboratory-based serology.

First-line H. pylori treatment

Further information
View PPI drug records
NICE dyspepsia and GORD guidance
MIMS Gastroenterology Clinic

Patients who test positive for H. pylori should begin with a 7-day, twice-daily triple-therapy regimen comprising a proton pump inhibitor (PPI), amoxicillin, and either clarithromycin or metronidazole. Healthcare professionals should take into account previous exposure to clarithromycin or metronidazole and choose the treatment regimen with the lowest acquisition cost. If the patient has a penicillin allergy, a combination of a PPI, clarithromycin and metronidazole is advised.

The above regimens eradicate H. pylori in about 85% of cases. Treatment failure can indicate poor compliance or antibacterial resistance. 

Second-line treatment of H. pylori

Patients who still have symptoms after first-line eradication treatment should receive a 7-day, twice-daily course of treatment with a PPI, amoxicillin and either clarithromycin or metronidazole (whichever was not used first-line). A quinolone or tetracycline (whichever has the lowest acquisition cost) should be used if the patient has previous exposure to clarithromycin and metronidazole.

If a patient is allergic to penicillin and has not previously been treated with a quinolone, a PPI should be given with metronidazole and levofloxacin.

Quadruple H. pylori therapy with bismuth

If a patient with penicillin allergy requires first-line treatment and has already received clarithromycin, or requires second-line treatment and has already received a quinolone, combining a PPI with bismuth, metronidazole and tetracycline is recommended. This regimen is not included in the MIMS summary, however, following the recent discontinuation of De-Noltab (tri-potassium di-citrato bismuthate), the only bismuth product for which there is UK clinical experience in this setting.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases